ENTA Enanta Pharmaceuticals, Inc.

NASDAQ
$13.16

Enanta Pharmaceuticals, Inc. (ENTA) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.63 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -4.2% since its last earnings release on August 10, 2026.

Enanta Pharmaceuticals Missed Consensus Estimates
Monday, August 10, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Sep 2026
Nov 9
Monday · 4:00 PM ET
Earnings Whisper
-
vs ($0.63)
Rev est $15.59M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $13.41

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals Inc is a biotechnology company. It is engaged in the research and development of small molecule drugs for infectious diseases. The Company uses its chemistry-driven approach & drug discovery capabilities to develop its products.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow